Perspective Therapeutics, Inc. (CATX)
| Market Cap | 417.41M +160.4% |
| Revenue (ttm) | 618,000 -58.0% |
| Net Income | -111.13M |
| EPS | -1.36 |
| Shares Out | 114.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,451,024 |
| Open | 3.910 |
| Previous Close | 3.940 |
| Day's Range | 3.650 - 4.060 |
| 52-Week Range | 1.955 - 6.160 |
| Beta | 1.76 |
| Analysts | Strong Buy |
| Price Target | 12.93 (+253.28%) |
| Earnings Date | May 11, 2026 |
About CATX
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-α-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2... [Read more]
Financial Performance
In 2025, Perspective Therapeutics's revenue was $884,000, a decrease of -39.20% compared to the previous year's $1.45 million. Losses were -$103.12 million, 30.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CATX stock is "Strong Buy." The 12-month stock price target is $12.93, which is an increase of 253.28% from the latest price.
News
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatment...
Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The alpha emitter platform demonstrates strong efficacy and safety in NETs, with a 43–50% response rate and minimal kidney toxicity. Manufacturing and regulatory readiness are advancing, with phase III preparations and new facilities underway. Additional pipeline programs will have data updates at ASCO and later this year.
Perspective Therapeutics doses first patients in two Phase 1/2a studies
Perspective Therapeutics (CATX) announced that the first patients were dosed with (212Pb)VMT-alpha-NET and (212Pb)PSV359 in two new cohorts of Phase 1/2a studies in neuroendocrine tumors and solid tum...
Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies
SEATTLE, May 18, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneeri...
Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Four clinical programs are advancing, with VMT-α-NET showing strong efficacy and safety, and pivotal trial planning underway. Manufacturing expansion and robust cash reserves support continued growth, while additional pipeline assets and new facilities position the company for broad market impact.
Perspective Therapeutics price target lowered to $6 from $7 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Perspective Therapeutics (CATX) to $6 from $7 and keeps a Neutral rating on the shares. The Q1 report reinforced the…
Perspective Therapeutics reports Q1 EPS (25c), consensus (30c)
Reports Q1 revenue $76,000, consensus $137,180. “The first quarter of 2026 was marked by continued execution across our clinical programs and strengthening of our financial position,” said Thijs Spoor...
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results
SEATTLE, May 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneeri...
Perspective Therapeutics Earnings release: Q1 2026
Perspective Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Perspective Therapeutics Quarterly report: Q1 2026
Perspective Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Perspective Therapeutics to Provide Several Upcoming Corporate Updates
SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme...
Perspective reports results from Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET
Perspective Therapeutics (CATX) announced updated interim results from its ongoing Phase 1/2a clinical trial of (212Pb)VMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor t...
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatmen...
Perspective Therapeutics Proxy statement: Proxy filing
Perspective Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Perspective Therapeutics Proxy statement: Proxy filing
Perspective Therapeutics filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Perspective Therapeutics to Participate in Upcoming Investor Conferences
SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme...
Perspective Therapeutics price target raised to $13 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Perspective Therapeutics (CATX) to $13 from $12 and keeps a Buy rating on the shares. The firm updated the company’s model post…
Perspective Therapeutics price target raised to $8 from $7 at UBS
UBS analyst David Dai raised the firm’s price target on Perspective Therapeutics (CATX) to $8 from $7 and keeps a Buy rating on the shares.
Perspective Therapeutics price target raised to $13 from $11 at B. Riley
B. Riley raised the firm’s price target on Perspective Therapeutics (CATX) to $13 from $11 and keeps a Buy rating on the shares. Sentiment on Perspective Therapeutics has sharply improved…
Perspective Therapeutics price target raised to $8 from $7 at UBS
UBS analyst David Dai raised the firm’s price target on Perspective Therapeutics (CATX) to $8 from $7 and keeps a Buy rating on the shares.
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatme...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pionee...
Perspective Therapeutics Annual report: Q4 2025
Perspective Therapeutics has published its Q4 2025 annual report on March 16, 2026.
Perspective Therapeutics Earnings release: Q4 2025
Perspective Therapeutics released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Perspective Therapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Biren Amin initiated coverage of Perspective Therapeutics (CATX) with an Overweight rating and $16 price target The firm says the company’s pipeline of lead-212 radiotherapies po...